Key facts
- Slingshot Biosciences’s last known valuation is $138.0M (Jul 2025).
- It has raised $49.8M across 2 recorded rounds; the latest was Early Stage VC ($26.2M) in Jan 2023.
- Notable investors include Impact Assets, ARCH Venture Partners, Anterra Capital, Jeffrey Kim, Northpond Ventures — 7 tracked in total.
- Slingshot Biosciences has filed 4 Form Ds with the SEC since 2021, most recently Apr 2024 ($26.2M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Slingshot Biosciences
Funding rounds
2 roundsAbout Slingshot Biosciences
Developer of engineered synthetic cells designed to speed up complex drug research. The company specializes in measuring or estimating the quantity and standardization to be reached with cell analysis and precisely matching the forward and side scatter of white blood cells, enabling researchers to access advanced diagnostics and therapeutics by eliminating cold-chain restrictions and developing products for neglected and rare diseases.
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2012
- Employees
- 70
- Website
- slingshotbio.com/
- Ownership
- Privately Held (backing)
Slingshot Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Slingshot Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Slingshot Biosciences in its N-PORT filings yet. We sweep new filings monthly.